The survival period of adenocarcinoma bone metastasis in lung cancer is usually about 1-3 years, but the situation varies. If the genetic test suggests genetic mutation, gene targeting drug therapy can be given, including first, second and third generation targeted drugs such as gefitinib, erlotinib and oxitinib, which can effectively control the recurrence and metastasis of lung cancer against adenocarcinoma gene mutation, so that the survival period of patients can be one year, two years or even longer. However, if the genetic mutation is negative and there is no chance to take gene-targeted drugs, the general survival of lung cancer and adenocarcinoma bone metastasis is about 1-2 years, which can be extended appropriately by giving active chemotherapy or immunotherapy, as well as Chinese medicine to help eliminate evil.